Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors
International Journal of Hematology2015Vol. 102(3), pp. 342–348
Citations Over TimeTop 20% of 2015 papers
Masatoshi Sakurai, Takehiko Mori, Daiki Karigane, Keiichi Tozawa, Eri Matsuki, Takayuki Shimizu, Kenji Yokoyama, Hideaki Nakajima, Yoshinobu Kanda, Shinichiro Okamoto
Related Papers
- → Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML(2011)7 cited
- → Dasatinib: ten years of clinical practice worldwide(2016)3 cited
- → Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia(2009)9 cited
- → Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib(2008)2 cited
- → Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia(2010)1 cited